Taiwan's biggest CDMO secures FDA approval3 Sep 2019
Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.
Bora, a contract development and manufacturing organization (CDMO) that specializes in modified release (MR) and solvent production, has reported a successful FDA general inspection for its facility in Zhunan, Taiwan.
The publicly listed company recently hosted the site’s fifth successful inspection by the US regulatory body of its global supply facility located south-west of Taipei, with zero 483 observations.
The oral solid expert is Taiwan’s biggest CDMO, responsible for producing 52% of finished dosage form exports from Taiwan to the US and 11% from Taiwan to ROW. Its customers include some of the largest multinational pharmaceutical companies in the world.
Bobby Sheng, CEO at Bora Pharmaceuticals, commented: “Since acquiring this facility in early 2018, we have built a phenomenal team that is dedicated to adhering to strict quality standards. In fact, over 25% of the site’s workforce is devoted to quality assurance and control, so this approval is testament to them and the rest of our team.
“This latest FDA inspection underlines our commitment to servicing the US market and supporting our own future growth strategy. Our customers consistently praise our quality standards and efficiency, often saying the facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.
“We now intend to invest further into our US growth strategy to continue to be the most agile CDMO partner we can be.”
The Zhunan facility is also licensed by the MHRA, TFDA and is PIC/S certified. The site employs over 300 people and also offers small-scale R&D capabilities to support clients across all stages of the product lifecycle.
Sheng continued: “The advantages of modified release drugs are becoming increasingly recognized across the industry. Our ability to meet that growing demand with large-scale solvent manufacturing and at the same time handle complex drug products such as fixed dose combination products (FDC) at commercial scale has been a major advantage for us and a huge benefit to our customers.”
With a broad range of manufacturing technologies at its sites, Bora provides development to large-scale manufacturing, packaging, distribution, tech transfer, stability studies, and product life cycle management.
Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD
21 Feb 2020
Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.Read more
The game is on for connected devices
20 Feb 2020
Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma.Read more
Management healthcare consultancy opens new offices in New York and London
19 Feb 2020
The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.Read more
CPhI South East Asia rescheduled for July 2020
18 Feb 2020
Event move ensures extra precautions and safety measures takenRead more
Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics
18 Feb 2020
Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.Read more
Dr Reddy's to acquire Wockhardt divisions
18 Feb 2020
Deal sees 62 brands in multiple therapy areas and a manufacturing plant transfer to the companyRead more
Sartorius sharpens its brand focus
17 Feb 2020
The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.Read more
FDA success for MedPharm Centre of Excellence
14 Feb 2020
The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.Read more
Report predicts booming ASEAN generics export market for 2020
13 Feb 2020
The changing opportunities are attributed to rising GMP standards and increased regional harmonization.Read more
Partnership formed to deliver effective biopharma industry testing
12 Feb 2020
Stevanato and Pfeiffer Vacuum will provide biopharma companies with advanced container closure integrity analysis and testing protocols.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation